[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Baylor College of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":648},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,109,0,25,[9,53,81,104,128,151,190,222,244,266,293,322,347,367,392,411,436,459,482,508,531,551,578,602,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100609221","phase-1-nkg2dzeta-nk-cell-conditioning-with-c7rgd2car-t-cells-for-patients-with-relapsed-or-refractory-osteosarcoma-or-neuroblastoma-100609221",false,"NCT07211737","NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","(INCITE-ON) Phase I Study of i15.NKG2D.Zeta-NK Cell Conditioning in the Tumor Micro-environment in Combination With C7R.GD2.CAR-T for the Treatment of Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma","PROCUREMENT INCLUSION:\n\n1. Patients with Neuroblastoma that have persistent disease after standard treatment or have relapsed\u002Frefractory disease.\n\n   Or\n\n   Patients with Osteosarcoma that have persistent disease after standard treatment or have relapsed\u002Frefractory disease.\n2. Karnofsky\u002FLansky score of 60% or greater.\n3. Informed consent and assent (as applicable) obtained from parent\u002Fguardian and child.\n4. Greater than 1 year of age.\n\nPROCUREMENT EXCLUSION:\n\n1. History of hypersensitivity to murine protein-containing products.\n2. Known presence of Human Anti-Mouse Antibodies (HAMA).\n3. Active autoimmune disease (requiring immunosuppressive treatment in the past 6 months).\n4. Primary brain tumor or known brain metastases (on evaluation by MIBG and\u002For PET if applicable, CT\u002FMRI\u002FLP not required).\n\nTREATMENT INCLUSION:\n\n1. Patients with Neuroblastoma that have persistent disease after standard treatment or have relapsed\u002Frefractory disease.\n\n   Or\n\n   Patients with Osteosarcoma that have persistent disease after standard treatment or have relapsed\u002Frefractory disease.\n2. Karnofsky\u002FLansky score of 50% or greater\n3. Pulse Ox greater than or equal to 90% on room air\n4. AST less than 5 times upper limit of normal (less than 10 times upper normal if known with metastatic liver disease)\n5. Total bilirubin less than 3 times the upper limit of normal\n6. Serum creatinine less than 3 times upper limit of normal\n7. Available autologous T-cells with greater than or equal to 20% expressing GD2.CAR\n8. Informed consent and assent (as applicable) obtained from parent\u002Fguardian and child.\n9. Greater than 1 year of age.\n10. Recovered from acute toxic effects of all prior chemotherapy and investigational agents before entering this study.\n\nTREATMENT EXCLUSION:\n\n1. History of hypersensitivity to murine protein containing products (patients who have undergone desensitization and successful re-challenge without hypersensitivity reaction are eligible).\n2. Known presence of Human Anti-Mouse Antibodies (HAMA).\n3. Tumor potentially causing airway obstruction per investigator discretion.\n4. Pregnancy or lactation \u002F will not use birth control methods.\n5. Currently receiving immunosuppressive drugs (patients on low dose corticosteroids are eligible: less than 0.25 mg\u002Fkg\u002Fday of prednisone\u002Fequivalent).\n6. Primary brain tumor or known brain metastases (on evaluation by MIBG and\u002For PET if applicable, CT\u002FMRI\u002FLP not required).","ALL","1 Year","24 Years",{"count":21,"type":22},27,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The purpose of this study is to find the largest safe dose of i15.NKG2D.zeta-NK cells in combination with C7R.GD2.CAR-T cells, and additionally to evaluate how long they can be detected in patients' blood and what affect they have on patients' cancer.\n\nPatients eligible for this study have neuroblastoma or osteosarcoma that expresses a substance on the cancer cells called GD2. This cancer has either come back after treatment or did not respond to the standard or other investigational treatments or therapies used to treat it. There is no standard treatment for these types of advanced cancers at this time. This is a gene transfer research study using special immune cells called NK cells and T cells. NK cells and T cells are types of white blood cell that help the body fight infection.\n\nThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancers. This research study combines two different ways of fighting cancer: NK cells and T cells. T cells are special infection-fighting blood cells that can kill cells infected with viruses and tumor cells. NK cells, another kind of infection-fighting cell, can recognize a wide range of cells in distress, including tumor cells and cells that help protect tumor cells in the cancer environment. Both NK cells and T cells have been used individually to treat patients with cancers. They have shown promise, but have not been strong enough individually to cure most patients.\n\nInvestigators have found from previous research that we can put a new gene into T cells that will make them recognize GD2, a substance found on almost all neuroblastoma and osteosarcoma cells. We can also put a new gene into NK cells that help them fight the tumor environment. Investigators know that T cells and NK cells need substances called cytokines to survive but the cells do not get enough cytokines after infusion into the body; therefore, the investigators have added the genes C7R and IL15 into the T and NK cells, respectively, to give each cell a constant supply of cytokine that helps them to survive longer.\n\nThe C7R.GD2.CAR-T cells and i15.NKG2D.zeta-NK cells are investigational products not approved by the Food and Drug Administration.",[28,29,30,31],"Relapsed Neuroblastoma","Refractory Neuroblastoma","Relapsed Osteosarcoma","Refractory Osteosarcoma",[33,34,35,36,37,38,39],"Gene Therapy","CAR T cells","Neuroblastoma","Osteosarcoma","Immunotherapy","chimeric antigen receptor","NK Cell","NOT_YET_RECRUITING","2026-06-30",{"date":43,"type":44},"2026-07-01","ACTUAL",{"date":46,"type":22},"2026-08",{"date":48,"type":22},"2044-04",{"name":50,"class":51},"Baylor College of Medicine","OTHER",1,{"id":54,"slug":55,"hasResults":12,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":65,"conditions":66,"keywords":68,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":52},"100505916","phase-2-high-dose-albumin-in-refractory-ascites-100505916","NCT05867602","High Dose Albumin in Refractory Ascites","Clinical Efficacy of High-dose Albumin Administration Versus Standard Dose in Patients With Advanced Cirrhosis: Open Label Randomized Clinical Trial","Inclusion Criteria:\n\n1. Age \\> 18 years.\n2. patients diagnosed with liver cirrhosis.\n3. Refractory ascites which is defined as ascites failing to resolve after maximum tolerable dose of diuretics, and usually require frequent paracentesis.\n\nExclusion Criteria:\n\n1. Patients \\\u003C 18y\n2. patients with no history of liver cirrhosis\n3. patients with refractory ascites but have transjagular intrahepatic portosystemic shunts (TIPS) with previous 3 months\n4. Patients with ascites due to other causes, including cardiac, malignant","18 Years",{"count":62,"type":22},100,[64],"PHASE2","Advanced cirrhosis with complications is a serious problem imposing a heavy financial burden on health care system. Moreover, ascites is associated with increase in mortality rates among cirrhotic patients. Ascites pathogenesis is multifactorial including: portal hypertension; splanchnic and peripheral arterial vasodilation; and neurohumoral activation. Current management strategies include dietary sodium restriction and diuretic therapy, however, this strategy put patients at the risk of intravascular volume depletion, renal impairment, hepatic encephalopathy and hyponatremia. Moreover, around 10% of patients do not respond to this strategy (termed: diuretics resistant) with 50% of them die within 6 months. This sub-group is managed by frequent large volume paracentesis along with intravenous albumin administration and are usually considered for liver transplantation (LT) and TIPS. Nonetheless, Frequent paracentesis increases the risk of infection, bleeding, bowel perforation, paracentesis-induced circulatory dysfunction (PICD) and renal dysfunction in this sub-group of patients. The beneficial effect of human albumin might result from blood volume expansion tapering activated vasoconstrictor and sodium-retaining systems improving renal perfusion, hence regular infusion of albumin may be beneficial to prevent development of ascites and to improve survival. The positive effects of albumin are supported by previous studies; Romanelli et al, showed a significant increase in survival rate among cirrhotic patients with ascites when compared to those who did not receive albumin. Moreover, a randomized multicenter open label trial published in lancet last year, demonstrated that long term albumin administration improved 18-month survival, decreased the use of paracentesis and decrease in the incidence of cirrhosis related complications among cirrhotic patients with ascites. As of today, there's a limited use of regular high dose albumin in cirrhotic patients with ascites in US, despite being used elsewhere in the world as previously stated.\n\nThe investigators wish to study long-term efficacy of human albumin administration in patients with decompensated cirrhosis to assess safety and efficacy, and prevention of complications of cirrhosis.",[67],"Ascites",[69,70,71,72],"refractory ascites","liver cirrhosis","HRS","High dose albumin","RECRUITING","2026-06-26",{"date":41,"type":44},{"date":77,"type":44},"2019-03-25",{"date":79,"type":22},"2027-06-25",{"name":50,"class":51},{"id":82,"slug":83,"hasResults":12,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":88,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":23,"phases":91,"briefSummary":93,"conditions":94,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":52},"100464108","improving-comprehensive-care-of-cancer-patients-100464108","NCT05323409","Improving Comprehensive Care of Cancer Patients","Optimise: Improving Comprehensive Care of Cancer Patients With Comorbidities","Inclusion Criteria:\n\n* For patients: 1) new diagnosis or within three months of treatment initiation for early-stage breast (I-IIIB), GI (Stage I-III), or hematologic (Stage I-III) cancer 2) treatment with standard, definitive therapies (may include one or more modalities) 3) presence of one or more chronic comorbidities (e.g., diabetes, hypertension) and\u002For unhealthy lifestyle behaviors (e.g., overweight\u002Fobesity, current smoker, alcohol use) that require ongoing management during cancer treatment 4) age \\>18 years 5) fluency in English or Spanish 6) ability to provide informed consent 7) assignment to a Harris Health oncologist and PCP who are willing to participate and will provide informed consent.\n\nFor healthcare providers: 1) Person is an oncologist or PCP who treats patients with breast, GI, or hematologic malignancies at Harris Health BT\u002FSmith Clinic\n\nExclusion Criteria:\n\n* For Patients: Significant cognitive impairment or Lack of capacity to consent For Providers: None",true,{"count":90,"type":22},340,[92],"NA","Cancer survivors have unique healthcare needs, including managing serious late effects, ongoing surveillance, lifestyle modifications to reduce second cancer risk, and psychosocial support. Nearly 70% of survivors have at least one comorbid chronic condition in addition to cancer, which complicates the delivery of quality cancer care. Medically underserved patients, who bear the highest burden of multiple chronic conditions, are at increased risk for poor outcomes during and after cancer treatment. Enhancing communication and collaboration between oncologists and primary care providers (PCPs) could improve health outcomes and care transitions for these patients, who often lack healthcare knowledge and access to supportive care.\n\nThis study evaluates a novel shared care model for cancer survivors with chronic comorbidities, called OPTIMISE (Oncology-Primary Care Partnership to Improve Comprehensive Survivorship Care), in the largest safety-net healthcare system in Houston, Texas. Three hundred newly diagnosed breast, gastrointestinal, and hematological cancer patients being treated with curative intent and having comorbidities requiring ongoing management will be randomized to either OPTIMISE or Usual Medical Care (UMC). UMC patients will receive cancer treatment directed by their oncologist, a survivorship care plan (SCP) at the end of active treatment, and surveillance visits based on national guidelines.\n\nOPTIMISE patients will: 1) have an oncology nurse navigator assigned to their care team at diagnosis to facilitate oncologist-PCP communication; 2) receive coordinated care between their oncologist and PCP throughout cancer treatment and surveillance, facilitated by structured communication and referral processes; 3) receive an SCP that incorporates comorbidity management; and 4) follow a risk-stratified shared care model where some routine oncologist follow-up visits are replaced by PCP visits. Aim 1a evaluates OPTIMISE's impact on patient chronic disease self-management (primary outcome) and quality of life (secondary outcome). Aim 1b explores OPTIMISE's effects on healthcare use and patient unmet needs during and after treatment. Aim 2 examines OPTIMISE's impact on oncologist and PCP attitudes and care coordination. Aim 3 elucidates patient- and system-level factors influencing implementation outcomes. If effective, OPTIMISE could expand to other cancers and enhance care transitions in various medical settings.",[95,96,97],"Breast Cancer","Gastrointestinal Cancer","Hematologic Cancer",{"date":41,"type":44},{"date":100,"type":44},"2022-04-01",{"date":102,"type":22},"2027-06",{"name":50,"class":51},{"id":105,"slug":106,"hasResults":12,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":115,"conditions":116,"keywords":119,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},"100309842","locating-biomarkers-in-ocd-through-behavioral-tasks-100309842","NCT03313622","Locating Biomarkers in OCD Through Behavioral Tasks","Locating Biomarkers of Medically Intractable Obsessive Compulsive Disorder (OCD) Through the Use of Behavioral Tasks","Inclusion Criteria:\n\n* Diagnosis of OCD\n* Non-pregnant if female\n* Minimum score of 16 on Y-BOCS\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Those not meeting inclusion criteria listed above\n* Lifetime diagnosis of psychotic disorders such as schizophrenia\n* Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine\n* Deemed at high risk of suicidal behavior or impulsivity\n* Pregnant or plans to become pregnant in the next 24 months","65 Years",{"count":113,"type":22},20,"OBSERVATIONAL","Subjects that have a diagnosis of OCD will participate in a clinical interview and cognitive tasks, during which they will be exposed to their individual OC stressors or will be asked to make decisions related to information value and quantity while measuring neural activity and filming facial reactions. This will assist investigators to look for biomarkers of that change. This study offers a unique opportunity to develop biomarkers for key domains of OCD, and other neuropsychiatric disorders, that are grounded in brain neurocircuitry at the individual-patient level.\n\nSubjects will participate in a clinical interview (Day 1), and then tasks+EEG (Day 2). Day 1 will be 4 hours or less, and Day 2 will be 2.5 hours or less.",[117,118],"OCD","Obsessive-Compulsive Disorder",[117,120],"Obsessive Compulsive Disorder",{"date":41,"type":44},{"date":123,"type":22},"2027-03",{"date":125,"type":22},"2028-03",{"name":50,"class":51},3,{"id":129,"slug":130,"hasResults":12,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":135,"maxAge":60,"enrollmentInfo":136,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":52},"100644743","postoperative-pain-after-pediatric-adenotonsillectomy-with-ketorolac-or-ibuprofen-100644743","NCT07672418","Postoperative Pain After Pediatric Adenotonsillectomy With Ketorolac or Ibuprofen","Assessment of Postoperative Pain Outcomes Following Pediatric Adenotonsillectomy and the Impact on Non-Steroidal Anti-Inflammatory Drugs","Inclusion Criteria:\n\nScheduled for outpatient adenotonsillectomy Age 13-18 years ASA physical status I-III Patient or parent has access to a phone with text-messaging capability Patient assent Parent or legal guardian consent\n\nExclusion Criteria:\n\nInpatient admission or planned 23-hour observation Known hematologic condition or prior bleeding disorder Current anticoagulant use Known or suspected chronic kidney disease or solitary kidney Known or suspected liver disease or prior liver transplant Known or suspected mitochondrial disease or genetic anomaly Inability to self-report pain History of gastrointestinal ulcer or bleeding Allergy to acetaminophen, ibuprofen, or ketorolac Non-English or non-Spanish speaking Chronic pain or condition requiring frequent routine NSAID use Patient refusal Parent or guardian refusal","13 Years",{"count":137,"type":22},200,"This prospective observational study will evaluate postoperative pain after outpatient pediatric adenotonsillectomy in adolescents prescribed either acetaminophen with ibuprofen or acetaminophen with oral ketorolac after discharge, based on the prescribing preference of the otolaryngology surgeon. Participants will complete text-message surveys after discharge to assess pain severity, medication administration, and functional recovery for up to 14 days.",[140,141,142],"Sleep","Pediatrics","Adenotonsillectomy","2026-06-23",{"date":145,"type":44},"2026-06-29",{"date":147,"type":22},"2026-06-24",{"date":149,"type":22},"2027-06-30",{"name":50,"class":51},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":23,"phases":161,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":189,"locationsCount":4},"100644678","supporting-access-for-latinx-underserved-in-diabetes-management-salud-m-acceptance-based-coping-skills-for-hispaniclatinx-military-patients-with-type-2-diabetes-100644678","NCT07674628","Supporting Access for Latinx Underserved in Diabetes Management (SALUD-M): Acceptance Based Coping Skills for Hispanic\u002FLatinx Military Patients With Type 2 Diabetes","Supporting Access for Latinx Underserved in Diabetes Management (SALUD-M): An Equity-Driven Study of Acceptance Based Coping Skills for Hispanic\u002FLatinx Military Patients With Type 2 Diabetes Mellitus","SALUD-M","Inclusion Criteria:\n\n(a) Patients ages 18-70, (b) diagnosis of T2DM, (c) current HbA1c (drawn within 6 months) of 7.5% or greater (may be taking oral agents or injectables for diabetes control), (d) evidence of avoidance coping (score \\\u003C48.4 \\[published mean\\] on the Acceptance and Action Diabetes Questionnaire16) or poor self-management skills (score \\\u003C published mean on 2+ subscales of the Summary of Diabetes Self-Care, Activities37), (e) self-described as Hispanic\u002FLatino\u002FLatina\u002FLatinx, (f) preferred language of English or Spanish, (g) receiving care at the study site clinic.\n\nExclusion Criteria:\n\n(a) End-stage renal disease (on dialysis), (b) a medical condition or life circumstance that would contraindicate participation, (c) proliferative diabetic retinopathy precluding participation, (d) inability to read\u002Fcomprehend the informed consent process or study instructions, (e) pregnant or planning to become pregnant in the next 6 months.","70 Years",{"count":62,"type":22},[92],"People of Hispanic or Latino\u002Fa\u002Fx (\"H\u002FL\") ethnicity, including US military servicemembers, Veterans, and their families, experience a higher prevalence of type 2 diabetes and more challenges managing diabetes than non-Hispanic White populations. Uncontrolled diabetes is linked with lower quality of life, diabetes-related emotional distress, and severe medical problems. There are many reasons for this difference, including lack of culturally appropriate and bilingual Spanish healthcare services. Additionally, military patients may have additional barrier accessing behavioral health care, which an important part of treatment for many people with diabetes, such as stigma and unique schedule challenges.\n\nTherefore, this study aims to overcome these barriers and improve healthcare and health outcomes for H\u002FL military patients. We will test a values-based behavior change program, delivered using video telehealth by a bilingual English-Spanish language health coach. The 10-week Acceptance Based Coping (ABaCo) skills program includes 7 virtually-delivered lessons and was developed by the study team in partnership with civilian community health workers and patients. This study will test the helpfulness of ABaCo delivered by a health coach fluent in English and Spanish to military H\u002FL patients. This randomized controlled trial will examine changes in physical and mental health over 6 months for those who receive ABaCo, compared to those who receive usual healthcare. This project will also identify steps for implementing the ABaCo program in other military treatment facilities.\n\nThe ultimate goal of this study is to establish a helpful, easy-to-access, widely available program for H\u002FL military patients with type 2 diabetes that improves quality of life and blood sugar control, and lowers distress about diabetes. This study will also identify best approaches to providing ABaCo in military treatment facilities, providing lessons learned to other large healthcare systems.",[164],"Type 2 Diabetes",[166,167,168,169,170,171,172,173,174,175,176,177,178,179,180,181,182,183,184],"type 2 diabetes","acceptance","Latino","Hispanic","Latinx","military","health coach","paraprofessional","virtual","telehealth","acceptance and committment therapy","diabetes distress","blood glucose","HbA1c","veteran","military treatment facility","randomized controlled trial","quality of life","values",{"date":145,"type":44},{"date":187,"type":22},"2026-06-15",{"date":149,"type":22},{"name":50,"class":51},{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":23,"phases":200,"briefSummary":201,"conditions":202,"keywords":206,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":221},"100413483","phase-1-ebv-specific-t-lymphocytes-for-treatment-of-ebv-positive-lymphoma-100413483","NCT04664179","EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","Constitutive IL7 (C7R) Modified EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma","CILESTE","1. INCLUSION CRITERIA AT TIME OF PROCUREMENT\n\n   1. Any patient, regardless of age or sex, with EBV-positive Hodgkin's or non Hodgkin's Lymphoma, (regardless of the histological subtype) or EBV (associated)- T\u002FNK-lymphoproliferative disease who may subsequently be eligible for the treatment component\n   2. EBV positive tumor (can be pending)\n   3. Weighs at least 10 kg\n   4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given a copy of informed consent.\n2. INCLUSION CRITERIA AT TIME OF INFUSION\n\n   1\\) Any patient regardless of age or sex, with diagnosis of either\n   1. EBV positive Hodgkin's lymphoma\n   2. EBV positive non-Hodgkin's Lymphoma (regardless of histologic subtype)\n   3. EBV (associated)-T\u002FNK-lymphoproliferative disease\n\n   AND either\n\n   A) In first or subsequent relapse or with persistent active disease despite therapy; OR\n\n   B) With active disease if immunosuppressive chemotherapy is contraindicated as determined by the study PI, in consultation with the primary provider as needed, e.g. patients who develop Hodgkin's disease after solid organ transplantation or if the lymphoma is a second malignancy, e.g. a Richter's transformation of CLL.\n\n   2\\) EBV positive tumor confirmed by pathology\n\n   3\\) Patients with life expectancy ≥ 6 weeks\n\n   4\\) Patients with bilirubin ≤ 3x upper limit of normal, AST ≤ 3x upper limit of normal, creatinine ≤ 2x upper limit of normal for age and Hgb ≥ 7.0 (may be a transfused value)\n\n   5\\) Pulse oximetry of \\>90% on room air\n\n   6\\) Patients should have been off other investigational therapy for 4 weeks prior to entry in this study.\n\n   7\\) Patients with a Karnofsky\u002FLansky score of ≥ 50\n\n   8\\) Informed consent explained to, understood and signed by patient\u002Fguardian. Patient\u002Fguardian given a copy of informed consent.\n3. EXCLUSION CRITERIA AT TIME OF PROCUREMENT\n\n   1\\. Known pregnancy or actively breastfeeding (pregnancy test is not required at the time of procurement).\n4. EXCLUSION CRITERIA AT TIME OF INFUSION\n\n   1. Pregnant or breastfeeding\n   2. Active and uncontrolled bacterial, viral or fungal infection\n   3. Current use of systemic corticosteroids (prednisone equivalent \\>0.5 mg\u002Fkg\u002Fday)\n   4. Bulky disease resulting in airway obstruction or risk for airway obstruction with further enlargement.",{"count":199,"type":22},52,[25],"This study is for patients that have a type of lymph gland disease called Hodgkin or non-Hodgkin Lymphoma or T\u002FNK-lymphoproliferative disease which has come back or has not gone away after treatment, including the best treatment the investigators know for these diseases.\n\nSome patients with Lymphoma or T\u002FNK-lymphoproliferative disease show signs of virus that is sometimes called Epstein Barr virus (EBV) that causes mononucleosis or glandular fever (\"mono\") before or at the time of their diagnosis. EBV is found in the cancer cells of up to half the patients with Hodgkin's and non-Hodgkin Lymphoma, suggesting that plays a role in causing Lymphoma. The cancer cells (in lymphoma) and some immune system cells infected by EBV are able to hide from the body's immune system and escape destruction.\n\nT cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including cells infected with viruses and tumor cells. T cells have been used to treat patients with cancers. T cells, that have been trained to kill EBV infected cells can survive in the blood and affect the tumor. The investigators have treated over 80 people on studies using T cells to target these diseases. About half of those patients who had disease at the time they got the cells had responses including some patients with complete responses.\n\nThe investigators think that if T cells are able to last longer in the body, they may have a better chance of killing EBV and EBV infected tumor cells. Therefore, in this study the investigators will add a new gene to the EBV T cells that can cause the cells to live longer called C7R. The investigators know that T cells need substances called cytokines to survive and the cells may not get enough cytokines after infusion into the body. The investigators have added the gene C7R that gives the cells a constant supply of cytokine and helps them to survive for a longer period of time.\n\nThe purpose of this study is to find the largest safe dose of C7R-EBV T cells, and additionally to evaluate how long they can be detected in the blood and what affect they have on cancer.",[203,204,205],"EBV-Related Hodgkin Lymphoma","EBV-Related Lymphoproliferative Disorder","EBV Related Non-Hodgkin's Lymphoma",[207,208,209,210,211,212],"non-Hodgkin's Lymphoma","EBV (associated)-T\u002FNK-lymphoproliferative disease","EBV SPECIFIC T-LYMPHOCYTES","EBV","Hodgkin's Lymphoma","lymphoma relapse","2026-06-22",{"date":215,"type":44},"2026-06-25",{"date":217,"type":44},"2022-10-31",{"date":219,"type":22},"2042-11",{"name":50,"class":51},4,{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":52},"100631143","clinical-outcomes-safety-and-effectiveness-of-speedboat-ultraslim-in-per-oral-endoscopic-myotomy-poem-100631143","NCT07496840","Clinical Outcomes, Safety, and Effectiveness of Speedboat UltraSlim™ in Per-Oral Endoscopic Myotomy (POEM)","Clinical Outcome, Safety, and Effectiveness Assessment of Speedboat Ultraslim™ Surgical Device in the Performance of Per-Oral Endoscopic Myotomy (POEM)","SU-POEM","Inclusion Criteria:\n\n* Adult patients (≥18 years of age)\n* Diagnosed with achalasia or other esophageal motility disorders\n* Scheduled to undergo clinically indicated per-oral endoscopic myotomy (POEM) using the Speedboat UltraSlim™ device\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Patients not considered appropriate candidates for POEM by the principal investigator or treating physician",{"count":231,"type":22},40,"This study is a prospective registry designed to evaluate the clinical outcomes, safety, and effectiveness of per-oral endoscopic myotomy (POEM) performed using the Speedboat UltraSlim™ device in patients with achalasia or other esophageal motility disorders.\n\nParticipants included in this registry are those undergoing clinically indicated POEM as part of standard of care. No experimental interventions will be performed as part of this study. Patients will be approached for participation after the clinical decision to perform POEM has already been made.\n\nData will be collected through review of electronic medical records and procedural documentation, including patient demographics, procedural details, and clinical outcomes. Follow-up data will be collected at predefined time points (e.g., 30 days, 3 months, 6 months, and up to 1 year) to assess symptom improvement, procedural success, and adverse events.\n\nThe primary objective of the study is to assess technical success, clinical success, and safety outcomes associated with the use of the Speedboat UltraSlim™ device during POEM procedures.\n\nThis registry poses minimal risk to participants, as all procedures are performed as part of routine clinical care. No additional interventions beyond standard care are required for participation.",[234,235],"Esophageal Motility Disorders","Achalasia","2026-06-16",{"date":238,"type":44},"2026-06-17",{"date":240,"type":44},"2026-01-15",{"date":242,"type":22},"2027-09-30",{"name":50,"class":51},{"id":245,"slug":246,"hasResults":12,"nctId":247,"briefTitle":248,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":159,"enrollmentInfo":250,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":252,"conditions":253,"keywords":256,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":259,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":265},"100561921","neurophysiological-investigation-of-the-approach-avoidance-axis-in-ocd-applications-to-neuromodulation-100561921","NCT06596447","Neurophysiological Investigation of the Approach-avoidance Axis in OCD: Applications to Neuromodulation","Inclusion Criteria:\n\n1. Principal diagnosis of OCD per DSM-5;\n2. Adult between ages 18 and 64;\n3. At least a five-year history of treatment-refractory OCD that causes substantial subjective distress and impairment in functioning;\n4. Minimum score of 28 on the Y-BOCS;\n5. Failed an adequate trial of at least three SSRIs;\n6. Failed an adequate trial of clomipramine;\n7. Failed augmentation of one or more of the aforementioned drugs with at least one anti-psychotic medication;\n8. Failed an adequate trial of CBT for OCD, defined as 25 hours of documented exposure and response prevention (ERP) by an expert therapist;\n9. Stable psychotropic medical regimen for the month preceding surgery;\n10. Principal diagnosis of OCD who are approved by our multi-disciplinary team to undergo DBS surgery within two months of enrollment;\n11. Ability to provide fully informed, written consent;\n12. Availability of a family member or significant other who is willing to accompany patients to study visits if necessary.\n\nExclusion Criteria:\n\n1. Lifetime diagnosis of psychotic disorder such as schizophrenia;\n2. Alcohol or substance abuse\u002Fdependence within 6 months, excluding nicotine;\n3. Concern for high risk of suicidal behavior or impulsivity;\n4. Patient is \\[regnant or plans to become pregnant in the next 24 months;\n5. Need for diathermy;\n6. Existence of any neurological or medical condition\u002Fdisorder that makes the individual, in the opinion of the study team, a poor candidate to participate in the intended study procedures\n7. Comorbid psychiatric disorder that, in the opinion of the study team, may interfere with the candidate's ability to participate in study activities;\n8. Primary diagnosis of a Hoarding Disorder.",{"count":251,"type":22},10,"We will recruit 10 patients with OCD meeting established criteria for surgical evaluation. Following informed consent and baseline evaluations, each will be implanted with permanent DBS SenSight leads and the Medtronic Percept RC IPG, which has on-device neural recording capability and rechargeability.\n\nWe will collect a broad array of neurobehavioral data across two environments with complementary advantages: the clinic and the home. The first 2 Aims test our mechanistic hypothesis by studying the pattern of VS neural activity in the controlled environment of the lab\u002Fclinic during two complementary paradigms: one based on a psychophysical behavioral task, the other based on ERP, a therapeutic behavioral intervention. The third aim tests this hypothesis in an ambulatory, naturalistic setting with chronic neural on-device recordings paired with time resolved behavioral measures. We will investigate a possible common neural basis underlying approach and avoidance across these 3 paradigms.\n\nSubjects will participate in research at 7 critical timepoints during routine clinic visits (Fig. 4): before implant, 1 day before DBS activation, immediately after DBS activation, 2 weeks, 3 months, 6 months, and 12 months after DBS initiation. At these timepoints, patients will complete clinical assessments, perform the Probabilistic Approach Avoidance Task (PAAT), and conduct exposure trials under the guidance of a psychologist. The clinic offers the most controlled environment and provides opportunities for collecting high temporal resolution behavior synchronized to local field potential (LFP) recordings. These data will allow us to identify the degree of overlap in the time-resolved neural activity driving individual decisions to approach potential rewards or avoid potential aversive stimuli (Aim 1), and resist performing compulsions in order to achieve relief after OCD symptoms are triggered (Aim 2).\n\nAt home, our goal is to investigate patient trajectories along the approach-avoidance axis as OCD symptoms improve (Aim 3). We will leverage passive, on device recordings that occur in the background of everyday life activities and synchronize these neural recordings with data collected via wearables, ecological assessments, and video diaries. Capturing neural and behavioral data in the home environment is essential for understanding the neural and behavioral changes that occur over longer timescales than individual clinical visits. The neurobehavioral biomarkers generated by this dataset will provide trackable readouts of clinical status that could inform therapeutic decision-making and enable data driven intervention.",[254,255],"Obsessive Compulsive Disorder (OCD)","Neuromodulation",[120,117,257,258],"Deep Brain Stimulation","DBS",{"date":238,"type":44},{"date":261,"type":22},"2026-08-01",{"date":263,"type":22},"2030-07-31",{"name":50,"class":51},2,{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":23,"phases":276,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":265},"100363560","phase-1-tetravi-multivirus-ctl-for-treatment-of-ebv-cmv-adenovirus-and-bk-infections-post-allogeneic-sct-100363560","NCT04013802","TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.","Administration of Most Closely HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, and BK Virus Infections Post Allogeneic Stem Cell Transplant","TETRAVI","Inclusion Criteria:\n\n1. Prior myeloablative or non-myeloablative allogeneic hematopoietic stem cell transplant using either bone marrow or peripheral blood stem cells or single or double cord blood.\n\n   Or Received CAR-T cells targeting an antigen expressed on normal virus specific T cells\n2. Treatment for Infection\u002FDisease will fall into one of 3 categories (options):\n\n   * Option 1: Persistent, increasing or recurrent infections despite 7 days of standard therapy;\n\n     * a. CMV: Treatment of persistent or relapsed CMV disease or infection after standard therapy. For CMV infection, standard therapy is defined as antiviral therapy with ganciclovir, foscarnet, letermovir or cidofovir. 56, 57\n\n       * i. CMV disease: defined as the demonstration of CMV by biopsy specimen from visceral sites (by culture or histology) or the detection of CMV by culture or direct fluorescent antibody stain in broncheoalveolar lavage fluid in the presence of new or changing pulmonary infiltrates or changes consistent with CMV retinitis on ophthalmologic examination.\n       * ii. CMV infection: defined as the presence of CMV positivity as detected by PCR or pp65 antigenemia or culture from ONE site such as stool or blood or urine or nasopharynx or bronchoalveolar lavage.\n     * b. Adenovirus: Treatment of persistent adenovirus infection or disease despite standard therapy. Standard therapy is defined as antiviral therapy with cidofovir.\n\n       * i. Adenovirus infection: defined as the presence of adenoviral positivity as detected by PCR or culture from ONE site such as stool or blood or urine or lung or nasopharynx.\n       * ii. Adenovirus disease: defined as the presence of adenoviral positivity as detected by PCR, DFA or culture from two or more sites such as stool or blood or urine or lung or nasopharynx.\n     * c. EBV: For treatment of persistent EBV infection despite standard therapy. For EBV infection, standard therapy is defined as rituximab given at 375mg\u002Fm2 in patients for 1-4 doses with a CD20+ve tumor.58\n\n       * i. EBV infection: defined as: (1) Biopsy proven lymphoma with EBV genomes detected in tumor cells by immunocytochemistry or in situ PCR;\n       * ii. (2) Or clinical or imaging findings consistent with EBV lymphoma and\u002For elevated EBV viral load in peripheral blood.\n     * d. BK virus: Treatment of persistent BK virus infection or BK virus disease despite antiviral treatment with cidofovir or leflunomide. No clear standard treatment is defined (section 1.1.5). Cidofovir has been administered in low doses as well as high doses to HSCT patients with BK infections but no randomized trials are available proving its clinical efficacy.\n\n       * i. BK virus infection is defined as the presence of BK virus positivity as detected by PCR or culture in one site such as blood or urine or lung.\n       * ii. BK virus disease is defined as the presence of BK virus detectable by culture or PCR in blood or urine or other body fluids or lungs and symptoms of disease including, but not limited to persistent microscopic or macroscopic hematuria or detectable BK virus in more than one site.\n     * e. JC virus: Treatment of JC virus infection or disease without suitable alternative treatment option. Given the high homology (\\>90%) between JC and BK and the fact that BKVSTs targeting VP1 and Large T (as targeted in our multivirus MVSTs) have been administered to treat JCV-PML, and produced viral clearance from the cerebrospinal fluid, it is likely that our MVSTs will have efficacy against JC virus. Given the current lack of treatment options for JC virus infection or reactivation after HSCT and the risk of progression to JML, which is almost uniformly fatal, and the apparent activity of BK virus- directed T cells against JC virus infected cells, we propose including patients with JC virus on this study, unless a suitable alternative therapy is available.\n\n       * i. JC virus infection is defined as the presence of elevated JC virus levels as detected by PCR or positive culture in one site such as CSF or blood.\n       * ii. JC virus disease is defined as defined as the presence of JC virus detectable by culture or PCR in one or more sites such as blood or CSF and symptoms of disease including symptoms of PML OR detectable JC virus by PCR or culture in more than one site.\n   * Option 2: Early treatment for single or multiple infections with EBV, CMV, adenovirus, and\u002For BK virus will be allowed for patients deemed to be unable to tolerate standard therapy. Patients with multiple CMV, EBV, Adenovirus, and BK virus infections are eligible given that at least one infection is persistent despite standard therapy as defined above. Patients with multiple infections or reactivations are eligible to enroll.\n   * Option 3: For patients having adenovirus and BK virus, the requirement to fail one week of standard therapy would be waived if they meet one of the criteria below:\n\n     1. They are ≤100 days post- transplant\n     2. They are currently receiving other nephrotoxic agents or marrow-suppressive agents\n     3. They have adenovirus copy number ≥10,000 copies\u002Fml\n3. Clinical status at enrollment to allow tapering of steroids to equal or less than 0.5 mg\u002Fkg\u002Fday methylprednisolone (or equivalent).\n4. Hgb ≥ 7.0 gm\u002Fdl\n5. Available MVSTs must be partially HLA matched with recipient and HLA match must be verified by one of the Principal Investigators.\n6. Negative pregnancy test in female patients if applicable (childbearing potential who have received a reduced intensity conditioning regimen).\n7. Written informed consent and\u002For signed assent line from patient, parent or guardian.\n\nExclusion Criteria\n\n1. Patients receiving ATG, Campath or other immunosuppressive T cell monoclonal antibodies within 28 days of screening for enrollment.\n2. Patients with other uncontrolled infections. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment.\n\n   Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.\n3. Patients who are less than 28 days removed from their allogeneic hematopoietic stem cell transplant or who have received donor lymphocyte infusions (DLI) or CAR-T within 28 days.\n4. Patients with active acute GVHD grades II-IV.\n5. Uncontrolled relapse of malignancy\n6. Requirement for FiO2 \\> 50% oxygen to maintain oxygen saturation \\> 90% (peripheral pulse-ox). Note: patients requiring oxygen at FiO2\\\u003C=50% to maintain arterial oxygen saturation \\>90% are eligible to receive MVSTs if the reason for this oxygen requirement is believed attributable to the virus being treated.",{"count":275,"type":22},47,[25],"The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell transplant (HSCT). These cells may also have value in CAR-T recipients who have received a product that depletes virus specific T cells.\n\nThe patient must have had a myeloablative or non-myeloablative allogeneic HSCT using either bone marrow, single\u002Fdouble umbilical cord blood, or peripheral blood stem cells (PBSC) or CAR T cell product targeting an antigen expressed on virus specific T cells. After a transplant, while the immune system grows back, the patient is at risk for infection. Some viruses can stay in the body for life and are normally controlled by a healthy immune system, but if the immune system is weakened, like after a transplant, they can cause life threatening infections. He\u002Fshe must have had an infection with one or more of the following viruses -Epstein Barr virus (EBV), cytomegalovirus (CMV), adenovirus (AdV), Human polyomavirus type I (BKV), and human polyomavirus type II (JCV)- that has persisted or recurred despite standard therapy.\n\nIn this study, the investigators want to use white blood cells that have been trained to treat viral infections. In an earlier study the investigators showed that treatment with such specially trained T cells has been successful when the cells are made from the transplant donor. However as it takes 1-2 months to make the cells, that approach is not practical for patients who already have an infection. In a subsequent study, the investigators were able to create multivirus-specific T cells (VSTs) from the blood of healthy donors and created a bank of these cells. The investigators then successfully used these banked cells to treat virus infections after a stem cell transplant. In this study the investigators have further modified their production method to decrease the potential side effects and the investigators want to find out if they can use these banked VSTs to fight infections caused by the viruses mentioned above.",[279],"Viral Infection",[281,282,283,284],"cytomegalovirus (CMV)","BK virus","Epstein-Barr virus (EBV)","adenovirus","2026-06-09",{"date":287,"type":44},"2026-06-11",{"date":289,"type":44},"2021-03-08",{"date":291,"type":22},"2031-05-01",{"name":50,"class":51},{"id":294,"slug":295,"hasResults":12,"nctId":296,"briefTitle":297,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":304,"briefSummary":305,"conditions":306,"keywords":309,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":265},"100384670","phase-1-allogeneic-cd30car-ebvsts-in-patients-with-relapsed-or-refractory-cd30-positive-lymphomas-100384670","NCT04288726","Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas","A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas","Inclusion Criteria:\n\n1. Diagnosis and clinical course falling into one of the following categories:\n\n   1. Hodgkin lymphoma\n   2. Aggressive non-Hodgkin lymphoma\n   3. ALK-negative anaplastic T cell lymphoma or other peripheral T-cell lymphoma\n   4. ALK-positive anaplastic T cell lymphoma\n2. CD30-positive tumor as assayed in a CLIA certified Pathology Laboratory.\n3. Age 12 to 75.\n4. Bilirubin 2 times (or 3 times if the patient has Gilbert syndrome) or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of \\> 60%.\n10. Available allogeneic T cells with ≥15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n13. Informed consent explained to, understood by and signed by patient or guardian. Patient or guardian given a copy of the informed consent form.\n\nExclusion Criteria:\n\n1. Received an investigational cell therapy or vaccine within the past 6 weeks.\n2. Received an investigational small molecule drug within the past 2 weeks.\n3. Received CD30 antibody-based therapy within the previous 4 weeks.\n4. Received gemcitabine-containing chemotherapy within the previous 12 weeks\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction (determined at the investigators' discretion).\n8. Current use of systemic corticosteroids at a dose equivalent to higher than 10 mg\u002Fday of prednisone.\n9. Active significant, uncontrolled bacterial, viral or fungal infection.\n10. Symptomatic cardiac disease (NYHA Class III or IV disease).","12 Years","75 Years",{"count":303,"type":22},18,[25],"This study involved patients that have a cancer called diffuse large B cell lymphoma (DLBCL), NK and T cell lymphomas (NK\u002FTL) or classical Hodgkin lymphoma (cHL) (hereafter these 3 diseases will be referred to as lymphoma). Patients lymphoma has come back or not gone away after treatment. Because there is no standard treatment for the patients cancer at this time or because the currently used treatments do not work fully in all cases, the patients are being asked to volunteer in this research study.\n\nIn this study the investigators want to test a type of T cell made from a normal donor. The T cells the investigators will use are called Epstein Barr virus (EBV) specific T cells (EBVSTs) and are cells that the investigators have trained in the laboratory to recognize a EBV which is the virus that causes mono or kissing disease. Some patients with lymphoma have EBV in their cancer cells. Researchers have given T cell lines from normal donor EBVSTs to lymphoma patients who have EBV in their lymphoma cells and have seen responses in about half the patients. The cells have have been generated and are frozen in a bank. The cells are called \"allogeneic\" (meaning the donor is not related to the patient). CD30.CAR in EBV-specific T cells (called allogeneic CD30.CAR-EBVST) from the blood of healthy donors. The investigators are giving the cells to patients with lymphoma cells that express CD30. If the lymphoma cells also express EBV there may be some benefit from targeting both proteins.\n\nThe purpose of this study is to find out the highest safe dose of allogeneic CD30.CAR-EBVST cells given following chemotherapy and used to treat lymphoma. The investigators will learn the side effects of CD30.CAR-EBVST cells in patients and see whether this therapy may help lymphoma patients",[307,308],"Extranodal Natural Killer\u002FT-Cell Lymphoma, Nasal Type","Classical Hodgkin Lymphoma",[310,311,312,313],"CD30-Positive Lymphoma","Hodgkin lymphoma","non-Hodgkin lymphoma","CD30 CAR","2026-06-08",{"date":316,"type":44},"2026-06-10",{"date":318,"type":44},"2020-09-16",{"date":320,"type":22},"2037-06-01",{"name":50,"class":51},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":328,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":301,"enrollmentInfo":330,"targetDuration":4,"studyType":23,"phases":332,"briefSummary":333,"conditions":334,"keywords":336,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":341,"startDateStruct":342,"completionDateStruct":344,"leadSponsor":346,"locationsCount":265},"100279415","phase-1-cd30-car-t-cells-relapsed-cd30-expressing-lymphoma-rely-30-100279415","NCT02917083","CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)","Phase I Study of Relapsed CD30 Expressing Lymphoma Treated With CD30 CAR T Cells (RELY-30)","RELY-30","PROCUREMENT Inclusion Criteria:\n\n1. Diagnosis of relapsed\u002Frefractory HL or NHL.\n2. CD30 positive tumor as assayed in a CLIA certified pathology laboratory (result can be pending at this time)\n3. Hgb ≥ 7.0 (may be a transfused value)\n4. Informed consent explained to, understood by and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n5. Karnofsky or Lansky score of \\> 60%\n\nTREATMENT Inclusion Criteria:\n\n1. Diagnosis of relapsed\u002Frefractory HL or NHL.\n2. CD30-positive tumor as assayed in a CLIA certified pathology laboratory.\n3. Age 16 to 75 for the first three patients on a dose level; thereafter, if no DLT, patients aged 12 to 75 can be treated on that dose level.\n4. Bilirubin 1.5 times or less than the upper limit of normal.\n5. AST 3 times or less than the upper limit of normal.\n6. Estimated GFR \\> 70 mL\u002Fmin.\n7. Pulse oximetry of \\> 90% on room air\n8. EKG shows no significant arrhythmias\n9. Karnofsky or Lansky score of \\> 60%.\n10. Available autologous T cells with greater than or equal to 15% expression of CD30CAR determined by flow-cytometry.\n11. Recovered from all acute non-hematologic toxic effects of all prior chemotherapy.\n12. Adequate pulmonary function with FEV1, FVC and DLCO (or DLCO\u002FVA, as clinically appropriate) greater than or equal to 50% of expected corrected for hemoglobin.\n13. Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n14. Informed consent explained to, understood by and signed by patient or guardian.\n\nPROCUREMENT Exclusion Criteria:\n\n1. Active infection with HIV or HTLV (can be pending at this time).\n2. Active bacterial, fungal or viral infection.\n\nTREATMENT Exclusion Criteria:\n\n1. Currently receiving any investigational agents or received any tumor vaccines within the previous six weeks.\n2. Received anti-CD30 antibody-based therapy within the previous 4 weeks.\n3. Subjects with rapidly progressive disease, defined as kinetic failure to previous chemotherapy.\n4. Bulky disease (defined as a 10 cm or greater mass or mediastinal disease with a transverse diameter exceeding 33% of the transthoracic diameter).\n5. History of hypersensitivity reactions to murine protein-containing products.\n6. Pregnant or lactating.\n7. Tumor in a location where enlargement could cause airway obstruction.\n8. Current use of systemic corticosteroids at a dose equivalent to 0.5 mg\u002Fkg\u002Fday of prednisone or higher.\n9. Active hemorrhagic cystitis.\n10. Active bacterial, viral or fungal infection.\n11. Symptomatic cardiac disease (NYHA Class III or IV disease).",{"count":331,"type":22},60,[25],"The subject has a type of lymph gland cancer called Lymphoma.\n\nThe body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. T cells, also called T lymphocytes, are special infection-fighting blood cells that can kill other cells, including tumor cells or cells that are infected with germs. Both antibodies and T cells have been used to treat patients with cancers; they both have shown promise, but have not been strong enough to cure most patients. Investigators hope that both will work better together.\n\nInvestigators have found from previous research that they can put a new gene into T cells that will make them recognize cancer cells and kill them. They now want to test whether these genetically modified T cells given after chemotherapy will be more effective at killing cancer cells.\n\nThe gene that will be put into the T cells makes an antibody called anti-CD30. This antibody sticks to lymphoma cells because of a substance on the outside of the cells called CD30. Anti-CD30 antibodies have been used to treat people with lymphoma, but have not been strong enough to cure most patients.\n\nFor this study, the anti-CD30 antibody has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor. These CD30 chimeric receptor-activated T cells (CD30.CAR T cells) seem to kill some of the tumor, but they don't last very long and so their chances of fighting the cancer are unknown.\n\nSeveral studies suggest that the infused T cells need room to be able to multiply and grow to accomplish their functions, and that this may not happen if there are too many other T cells in circulation. Because of that, doctors may use chemotherapy drugs to decrease the level of circulating T cells prior to the CD30.CAR T cells infusion. This is called \"lymphodepletion\"\n\nCD30.CAR T cells have previously been studied in lymphoma patients.",[211,335],"Non-Hodgkin Lymphoma",[337,338,339,340],"chimeric antigen receptors","immunotherapy","CAR T-cells","lymphoma",{"date":316,"type":44},{"date":343,"type":44},"2017-05-08",{"date":345,"type":22},"2040-02",{"name":50,"class":51},{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":23,"phases":355,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":366,"locationsCount":4},"100621282","phase-4-comparison-of-conjunctival-goblet-cell-density-in-dry-eye-patients-treated-with-cyclosporine-01-dissolved-in-perfluorobutylpentane-vevye-or-generic-005-cyclosporine-emulsion-for-8-weeks-100621282","NCT07368595","Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks","CSAGCD","Inclusion Criteria:\n\n* 1\\. Male or female, 18 years of age or older at enrollment. 2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.\n\n  3\\. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:\n  1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.\n  2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme. 4. Unanesthetized Schirmer test score ≥ 5 and \\\u003C 15mm\u002F5 min in at least 1 eye at the enrollment visit.\n\n     5\\. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.\n\n     6\\. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.\n\n     7\\. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n\n     8\\. Have given written informed consent prior to any study related procedures. 9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.\n\n     Exclusion Criteria:\n* Inclusion Criteria:\n\nTo be eligible to participate in this trial, an individual must meet all the following criteria:\n\n1. Male or female, 18 years of age or older at enrollment.\n2. Have a history of DED, clinician diagnosed or patient reported, within the 6 months prior to the enrollment visit.\n3. Have both of these signs of DED in the same eye at the Enrollment (baseline) visit:\n\n   1. Total cornea fluorescein staining score ≥ 3 based on the modified National Eye Institute (NEI) grading scheme.\n   2. Total conjunctival lissamine green staining score ≥ 2 based on the modified NEI grading scheme.\n4. Unanesthetized Schirmer test score ≥ 5 and \\\u003C 15mm\u002F5 min in at least 1 eye at the enrollment visit.\n5. A SANDE eye discomfort visual analog questionnaire score of ≥ 35 at the enrollment visit.\n6. Good general and ocular health, as determined by the investigator using medical history and ophthalmic examination.\n7. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n8. Have given written informed consent prior to any study related procedures.\n9. Able and willing to follow study instructions and likely to complete all required study visits as assessed by the investigator.\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria at the enrollment visit will be excluded from entry into the study:\n\nOphthalmic:\n\n1. History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, interfere with the interpretation of the study results or subject safety, such as: significant conjunctival scarring; pterygium or nodular pinguecula; conjunctivitis, or inflammation not associated with DED; clinically significant anterior blepharitis (Staphylococcal or Demodex).\n2. Other significant ophthalmic disease requiring topical medication (e.g., glaucoma, ocular hypertension), or other ophthalmic disease which the investigator believes may interfere with study findings or interpretation.\n3. History of ocular surgery within 1 year prior to the Screening visit, including punctal cautery, corneal refractive, or anterior segment surgeries (e.g., cataract surgery or any surgery creating limbal or corneal incisions).\n4. History of corneal transplant in one or both eyes.\n5. Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, bacterial or fungal keratitis.\n6. Use of contact lenses in either eye within 90 days prior to the enrollment visit or planned use during the study.\n7. Punctal or intracanalicular plug present in either eyelid within 90 days prior to the enrollment visit or anticipated plug insertion or occlusion at any time during the study.\n8. Regular use, as assessed by the investigator, of lid hygiene or heat masks within 14 days prior to the Enrollment visit or any planned use during the study.\n9. Use of lid heating therapy (i.e., LipiFlow®, iLUX®, Thermal OneTouch, TearCare®) or Meibomian gland probing\u002Ftherapeutic expression within 90 days prior to enrollment or anticipated during the study.\n10. Use of Intense Pulsed Light (IPL) therapy on eyelids within 90 days prior to enrollment or anticipated during the study.\n11. Use of artificial tears within 24 hours prior to enrollment or anticipated use during the study.\n12. Use of any topical ocular cyclosporine A formulation (e.g., ocular cyclosporine \\[Restasis®, Cequa™, Vevye™, generics\\] within 1 year prior to enrollment. Use of lifitegrast \\[Xiidra®\\]), perfluorohexyloctane \\[Meibo™\\]), Tryptyr™, or any topical ocular corticosteroid, or any non-steroidal-anti-inflammatory agents within 90 days prior to enrollment or anticipated use during the study.\n13. Use of topical ocular autologous serum\u002Fplasma within 90 days prior to the enrollment or anticipated use during the study.\n14. Use of any topical ocular glaucoma medication within 30 days prior to enrollment or anticipated use during the study.\n15. Regular use, as defined by the investigator, of any other topical ocular medication not listed in Exclusion 11, 12, 13 or 14 within 14 days prior to the enrollment visit or anticipated use during the study (e.g., eye whitening products \\[Visine®, Lumify®\\], topical ocular antibiotics, topical ocular antihistamines, mast cell stabilizers, presbyopia correcting drops \\[e.g., Vuity™\\].\n16. Use of Tyrvaya™ (varenicline solution, nasal spray 0.03 mg) within 90 days prior to the enrollment visit or anticipated use during the study.\n17. Use of oral medications for the treatment of severe DED and\u002For Meibomian gland disease such as oral pilocarpine, oral cevimeline, oral macrolides, oral tetracyclines or tetracycline derivatives, and oral retinoids within 30 days prior to enrollment or anticipated use during the study.\n18. General\u002FSystemic:\n\n    Initiation, discontinuation, or change in dose of a systemic medication known to cause ocular drying (e.g., antihistamines or antidepressants) less than 30 days prior to enrollment or a change in dosage is anticipated during the study. Note: occasional short-term use of these medications, such as systemic antihistamines will be permitted, provided that use was not within 7 days prior to enrollment. Initiation, discontinuation, or change in dose of a systemic corticosteroid less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study. Note: Non-ocular topically applied corticosteroids (including topical creams, nasal sprays and inhalers) will be permitted during the study, and the dose is not required to be stable.\n19. Initiation, discontinuation, or change in dose of a systemic immunomodulator (e.g., hydroxychloroquine, methotrexate, cyclosporine) less than 60 days prior to the enrollment visit or a change in dosage is anticipated during the study.\n20. Use of an investigational product or device within 30 days prior to the Screening visit.\n21. At the enrollment visit, at the investigator's discretion, have uncontrolled or severe:\n\n    1. Systemic allergy\n    2. Rhinitis or sinusitis\n    3. Atopic dermatitis involving the eyelids\n22. History or presence of significant systemic disease (i.e.: cardiovascular, pulmonary, hepatic, renal, hematologic, immunologic). Significant is defined as any disease that, in the assessment of the Investigator, would put the safety of the subject at risk through participation, or would prevent or confound protocol-specified assessments (e.g., severe rheumatoid arthritis, severe systemic lupus erythematosus, uncontrolled immunodeficiency disease, etc.).\n23. Known allergies or sensitivity to the study interventions or study diagnostic agents, including sodium fluorescein, lissamine green, etc.\n24. Pregnant at enrollment, currently breastfeeding or plans to become pregnant or breastfeed during the study.",{"count":331,"type":22},[356],"PHASE4","This goal of this clinical trial is to compare the effects of two approved cyclosporine eye drops that have different concentrations and vehicles on the number of mucus producing conjunctival goblet cells in patients with dry eye disease to learn which one causes the greatest increase.\n\nThe main questions it aims to answer are:\n\nDoes one drug cause a greater increase in goblet cells? How many weeks does it take to see the difference?\n\nParticipants will:\n\nUse the eye drops every day for 2 months Visit the clinic once every 2 weeks for exams and tests",[359],"Dry Eye Disease (DED)","2026-06-02",{"date":362,"type":44},"2026-06-03",{"date":364,"type":22},"2026-09-01",{"date":102,"type":22},{"name":50,"class":51},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":88,"sex":17,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":378,"conditions":379,"keywords":381,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":386,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":52},"100537156","clinical-and-molecular-biomarker-studies-in-rai1-retinoic-acid-induced-1--related-disorders-100537156","NCT06274164","Clinical and Molecular Biomarker Studies in RAI1 (Retinoic Acid-Induced 1) -Related Disorders","Clinical and Molecular Biomarker Studies in RAI1-Related Disorders","Inclusion Criteria:\n\n* Patient group:\n\n  * Patients who have RAI1-related disorder confirmed by genetic testing including karyotyping, fluorescence in situ hybridization (FISH), array Comparative Genomic Hybridization (aCGH), single nucleotide polymorphism (SNP) array and next generation sequencing performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.\n  * Grossly intact hearing and vision as per parent report\n  * Age between 1 month to 60 years old\n  * Able to complete the study (i.e., travel to site and spend 1 day in Houston)\n  * Caregiver with spoken and written English at a level adequate to give informed assent (consent on behalf of the patient) for participation.\n\nControl group:\n\n* Healthy family member, not having a RA1-related disorder\n* Age between 5 years to 80 years old\n\nExclusion Criteria:\n\n* Patient group:\n\n  * Contraindication for blood draw or skin biopsy as determined by the enrolling provider (e.g., bleeding diathesis)\n  * Patients who are at high risk including ventilator\u002Ftracheostomy dependent, poorly controlled endocrine disorders, and unstable seizures (will be assessed by neurologist), end-stage renal disease.\n  * Participation in any investigational treatment study\n\nControl group:\n\n• Patients who have RAI1-related disorder confirmed by genetic testing.","1 Month","80 Years",{"count":377,"type":22},90,"Currently, there is no clinically available genetic-based treatment for RAI1 (Retinoic Acid-Induced 1) -related disorders other than symptomatic management and there are no established clinical or molecular biomarkers that could be used as measures for the efficacy of therapy in future treatment studies. Biomarkers are measures of what is happening inside the body, shown by the results of laboratory, imaging or other tests.\n\nBiomarkers can help doctors and scientists diagnose diseases and health conditions, monitor responses to treatment and see how a person's disease or health condition changes over time.\n\nThe goal of this observational and laboratory study is to develop clinical, neurophysiology and molecular biomarkers in RAI1-related disorders. The main question\\[s\\] it aims to answer are:\n\n* to characterize the disease features more precisely and analyze the differentiating and overlapping features of RAI1-related disorders (Smith-Magenis syndrome and Potocki-Lupski Syndrome)\n* to identify clinical, neurophysiology, and laboratory biomarkers that differentiate RAI1-related disorders one from another.\n\nParticipants will have to complete:\n\n* a clinical examination\n* a blood draw\n* a skin biopsy (optional)\n* a sleep study\n\nResearchers will compare patients' blood to control group's blood for biomarker studies.",[380],"RAI1 Gene 17P11.2 Deletion+Duplication",[382,383,384,385],"Smith-Magenis syndrome (SMS)","Potocki-Lupski Syndrome (PTLS)","RAI1-related disorders","Retinoic Acid-Induced 1-related disorders",{"date":362,"type":44},{"date":388,"type":44},"2024-03-13",{"date":390,"type":22},"2027-05",{"name":50,"class":51},{"id":393,"slug":394,"hasResults":12,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":12,"sex":17,"minAge":300,"maxAge":60,"enrollmentInfo":398,"targetDuration":4,"studyType":23,"phases":400,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":405,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":52},"100576254","effect-of-increased-physical-activity-and-stopping-evening-snacking-in-metabolic-health-in-youth-with-prediabetes-100576254","NCT06782906","Effect of Increased Physical Activity and Stopping Evening Snacking in Metabolic Health in Youth With Prediabetes","Inclusion Criteria:\n\n1. 12-18 years of age\n2. Having a diagnosis of prediabetes\n3. Engaging in frequent evening snacking\n4. Inadequate physical activity\n\nExclusion Criteria:\n\n1. Diagnosis of diabetes\n2. Significant history of chronic disease\n3. Evidence of significant liver or kidney disease;\n4. Any hormone replacement therapy; and\n5. Pregnancy.",{"count":399,"type":22},80,[92],"Non-healthy eating habits and a lack of exercise contribute to prediabetes and type 2 diabetes (T2D). Evening snacking is linked to abnormal weight gain in adults and healthy adolescents. Most adolescents do not get enough exercise. This study aims to look at the benefits of more exercise and stopping evening snacking in youth with prediabetes. The study lasts 8 weeks, and participants will be randomly assigned to either an intervention group or a standard of care group.",[403],"Prediabetes","2026-06-01",{"date":360,"type":44},{"date":407,"type":44},"2025-05-13",{"date":409,"type":22},"2029-09",{"name":50,"class":51},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":415,"acronym":416,"eligibilityCriteria":417,"healthyVolunteers":12,"sex":17,"minAge":418,"maxAge":60,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":425,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":430,"startDateStruct":431,"completionDateStruct":433,"leadSponsor":435,"locationsCount":265},"100576431","rethinking-rigidity-development-of-a-3d-printed-scoliosis-brace-with-varying-flexibility-100576431","NCT06785207","Rethinking Rigidity: Development of a 3D-Printed Scoliosis Brace With Varying Flexibility","3DSCOLIBRACE","Inclusion Criteria:\n\n1. Have a diagnosis of juvenile idiopathic scoliosis or adolescent idiopathic scoliosis\n2. Have a Cobb angle between 20-40 degrees\n3. Are between ages 8-18\n4. Present as Risser 2+ on x-ray\n5. Currently wear a traditionally fabricated scoliosis brace\n6. Have good brace adherence in current brace (self-reported to be 75% of prescribed time)\n7. Be an established patient of Align Clinic and Dr. Timothy Borden\n8. Speak English (survey and semi-structured interview will only be available in English)\n9. Assent and receive parental consent\n\nExclusion Criteria:\n\n1. Have a diagnosis other than juvenile idiopathic scoliosis or adolescent idiopathic scoliosis\n2. Have a Cobb angle outside the range of 20-40 degrees\n3. Present as Risser 0 or 1\n4. Do not currently wear a traditionally fabricated scoliosis brace\n5. Have poor adherence in their current brace\n6. Do not speak English\n7. Are not willing participate in the study","8 Years",{"count":420,"type":22},5,[92],"Scoliosis bracing is an effective treatment method for idiopathic scoliosis, but only if worn consistently for many hours a day. Unsurprisingly, brace discomfort is a significant deterrent against treatment adherence. For decades, custom braces for idiopathic scoliosis have been fabricated using one of three materials - copolymer, polypropylene, or polyethylene. The application of the biomechanical principles behind bracing have improved over the years, but the materials have not. The investigators' goal is to expand fabrication options by testing a 3D-printed scoliosis brace with variable flexibility. The aim is to improve patients' perceived brace comfort.\n\nAfter optimizing the brace design, the investigators will collect patient feedback about the design from currently braced participants. These participants understand what a standard brace feels like and will provide impactful feedback.",[424],"Scoliosis Idiopathic Adolescent Treatment",[426,427,428,429],"3D-printed scoliosis brace","scoliosis brace","scoliosis bracing","3D-printing",{"date":360,"type":44},{"date":432,"type":44},"2025-04-01",{"date":434,"type":22},"2026-10-31",{"name":50,"class":51},{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":442,"eligibilityCriteria":443,"healthyVolunteers":88,"sex":17,"minAge":418,"maxAge":444,"enrollmentInfo":445,"targetDuration":4,"studyType":23,"phases":447,"briefSummary":448,"conditions":449,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":453,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":52},"100530896","screens-sleep-circadian-rhythms-and-electronics-in-the-evening-study-100530896","NCT06192745","SCREENS: Sleep, Circadian Rhythms, and Electronics in the EveNing Study","Experimental Effects of Light And Content From Evening Screen Media Use On Children's Sleep, Executive Functioning, And Emotion Regulation","SCREENS","Inclusion Criteria:\n\n* children between 8.0 and 11.9 year old\n* Tanner stage 1 and 2\n* live with their parent(s) (biological or legal guardian at least 50% of the time and has a primary role of caring for the child).\n* Children who sleep between 8.5 to 11 hours per night habitually\n* Children must sleep alone most nights\n* parent and child able to communicate and read and write in English\n* The child does not have to have access to a mobile device (tablet or Phone), but if they do, the primary device they use has to be an a) Android OS ≥5.0 either used only by the study child or shared with others, b) Amazon Fire OS ≥5.0 that only the child uses or c) an Apple iOS ≥14.0 that only the child uses.\n* If the child's primary device is a Android or Amazon Fired device, the parent and child agree to install Chronicle App (Android or Amazon). If the child's primary device is an Apple device, the parent and child agree to allow us to gather usage screenshots from the primary iPad or iPhone.\n* Families must live in the greater Houston area.\n\nExclusion Criteria:\n\n* child blindness or colorblindness\n* significant vision problems\n* developmental or cognitive delays\n* diagnosis of a sleep or psychiatric disorder\n* diagnosed cognitive or learning impairment affecting executive functioning (e.g., attention deficit hyperactivity disorder)\n* medical conditions that impact sleep\n* taking medications that impact sleep\n* travel beyond 2 time zones in the month before starting the study","11 Years",{"count":446,"type":22},220,[92],"The proposed project aims to disentangle the impact of evening light exposure emitted from tablet devices from the impact of arousing media content on children's sleep regulation, circadian physiology and next-day emotion regulation and executive functioning.",[140,450,451,452],"Circadian Rhythm","Executive Function","Emotion Regulation",{"date":362,"type":44},{"date":455,"type":44},"2025-01-10",{"date":457,"type":22},"2028-08-30",{"name":50,"class":51},{"id":460,"slug":461,"hasResults":12,"nctId":462,"briefTitle":463,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":88,"sex":17,"minAge":60,"maxAge":466,"enrollmentInfo":467,"targetDuration":4,"studyType":23,"phases":469,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":404,"lastUpdatePostDateStruct":476,"startDateStruct":477,"completionDateStruct":479,"leadSponsor":481,"locationsCount":52},"100507005","integrating-food-rx-with-best-feeding-practices-with-efnep-100507005","NCT05881759","Integrating Food Rx With Best Feeding Practices With EFNEP","Integrating Food Rx With Best Feeding Practices for Chronic Disease Prevention Among EFNEP Participants","Inclusion Criteria:\n\n* Living in Harris or Fort Bend counties\n* being a parent of a child 4-8 years old\n* ability to speak in English or Spanish\n* have ready access to a telephone\n* have access to the Internet with a smart phone, a tablet, a laptop, or a desktop computer\n\nExclusion Criteria:\n\n* parents of children with disabilities and\u002For those on prescription medications that affect weight and\u002For appetite\n* parents who are not able to complete self-report questionnaires","64 Years",{"count":468,"type":22},375,[92],"To assess feasibility and acceptability of of integrating Food Rx and Best Feeding Practices with EFNEP participants via a pilot study.",[472,473,474,475],"Dietary Habits","Childhood Obesity","Food Selection","Feeding Behavior",{"date":360,"type":44},{"date":478,"type":44},"2024-01-15",{"date":480,"type":22},"2027-03-31",{"name":50,"class":51},{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":301,"enrollmentInfo":489,"targetDuration":4,"studyType":23,"phases":490,"briefSummary":491,"conditions":492,"keywords":496,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":503,"completionDateStruct":505,"leadSponsor":507,"locationsCount":265},"100609931","phase-1-novel-unedited-allo-cell-therapy-for-high-risk-t-cell-malignancies-using-cd7-specific-car-t-cells-100609931","NCT07220993","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells","Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car Expressed On T Cells (NEO-CRIMSON)","Procurement Inclusion Criteria:\n\n• Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LL), or T-non-Hodgkin Lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia\u002Flymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK\u002FT cell lymphoma, Mycosis fungoides\u002F Sezary Syndrome Stage IIB or higher))\n\nAND\n\nRelapsed post-allogeneic related donor (matched, mismatched, or haploidentical) HSCT from whom allogeneic CD7.CAR T cells can be manufactured.\n\nAND\n\n* suitable for allogeneic hematopoietic stem cell transplant (HSCT)\n* with a suitable donor identified by a FACT accredited transplant center\n* willing to proceed to transplant if the CD7.CAR treatment induces complete remission and the patient\u002Fdonor remain suitable candidates.\n\nUsing NMDP donor assessment criteria, suitability is defined as \"during the search process, a donor is fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up.\" Documentation of suitability will be confirmed by the investigator prior to treatment.\n\n\\*For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated.\n\n* CD7-positive tumor (≥20% CD7 positive blasts by flow cytometry or immunohistochemistry (tissue) assessed by a CLIA certified Flow Cytometry\u002FPathology laboratory).\n* Age ≤75 years old.\n* Hgb ≥ 7.0 g\u002FdL (can be transfused)\n* Life expectancy greater than 12 weeks\n* Patients must have an available partially-HLA matched allogeneic EBV-specific T cell line on a BCM IRB approved protocol which can be used as treatment in the event of uncontrolled EBV reactivation.\n* Informed consent explained to, understood by and signed by patient\u002FLAR. Patient\u002FLAR given copy of informed consent.\n\nProcurement Exclusion Criteria:\n\n* Active infection requiring antibiotics\n* Active infection with HIV\n* History of other cancer (except non-melanoma skin cancer or in situ breast cancer or cervical cancer) unless the tumor was successfully treated with curative intent at least 2 years before trial entry.\n\nPrior HSCT Donor Procurement Criteria:\n\n• Donor must be prior hematopoietic stem cell transplant donor for patient relapsed post-allogeneic HSCT who meets patient screening eligibility criteria and has signed screening informed consent.\n\nPrior transplant donors will be screened with the standard blood bank donor questionnaire, medical history, and testing for infectious disease markers (IDMs; which may be pending at the time of blood collection). Medical history may be obtained by the patient's primary\u002Freferring transplant team if collection is being done remotely. The physician assessment, donor questionnaire, and IDMs will be reviewed by the principal investigator or appropriate designee to confirm\u002Fprovide final eligibility determination and documented in the donor's medical record.\n\n• Informed consent explained to, understood by and signed by donor\u002FLAR. Donor\u002FLAR given copy of informed consent.\n\nTreatment Inclusion Criteria:\n\n• Diagnosis of recurrent T-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LL), or T-non-Hodgkin Lymphoma (T-NHL, including Angioimmunoblastic T-cell lymphoma (AITL), Enteropathy-associated T-cell lymphoma (EATL), Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), Peripheral T-cell lymphoma (PTCL) NOS, Anaplastic large cell lymphoma (ALCL), Adult T-cell leukemia\u002Flymphoma, T cell prolymphocytic leukemia with symptomatic disease, Extranodal NK\u002FT cell lymphoma, Mycosis fungoides\u002F Sezary Syndrome Stage IIB or higher))\n\nAND\n\nRelapsed post-allogeneic related donor (matched, mismatched, or haploidentical) HSCT AND prior allogeneic donor available to donate blood for allogeneic CD7.CAR T-cell manufacture\n\nAND\n\n* suitable for allogeneic hematopoietic stem cell transplant (HSCT)\n* with a suitable donor identified by a FACT accredited transplant center\n* willing to proceed to transplant if the CD7.CAR treatment induces complete remission and the patient\u002Fdonor remain suitable candidates.\n\nUsing NMDP donor assessment criteria, suitability is defined as \"during the search process, a donor is fit to proceed to the next step- whether high-resolution or confirmatory HLA testing OR donor work-up.\" Documentation of suitability will be confirmed by the investigator prior to treatment.\n\n\\*For T-NHL subjects, eligibility will be confined to disease stages where allogeneic HSCT is indicated.\n\n* CD7-positive tumor (≥20% CD7+ blasts or tumor cells by flow cytometry or immunohistochemistry (tissue) assessed in a CLIA certified Flow Cytometry\u002FPathology laboratory.\n* Age ≤75 years old.\n* Bilirubin less than 3 times the upper limit of normal.\n* AST less than 5 times the upper limit of normal.\n* Estimated GFR ≥ 50 mL\u002Fmin.\n* Pulse oximetry of \\> 90% on room air\n* Karnofsky or Lansky score of ≥ 60%.\n* Recovered from acute toxic effects of prior treatments (i.e. chemotherapy) at least one week before entering this study.\n* ≥ 60 days post-allogeneic HSCT at time of treatment.\n* Patients must have an available partially-HLA matched allogeneic EBV-specific T cell line on a BCM IRB approved protocol which can be used as treatment in the event of uncontrolled EBV reactivation.\n* Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded. The male partner should use a condom.\n* Informed consent explained to, understood by, and signed by patient\u002Fguardian. Patient\u002Fguardian given copy of informed consent.\n\nTreatment Exclusion Criteria:\n\n* Currently receiving any investigational agents or having received any tumor vaccines within the previous 4 weeks.\n* History of hypersensitivity reactions to murine protein-containing products.\n* Pregnant or lactating.\n* Tumor in a location where enlargement could cause airway obstruction (per investigator discretion).\n* Clinically significant infection or uncontrolled viral reactivation of EBV, CMV, Adv, BK-virus, or HHV-6.\n* Evidence of acute GVHD \\> Grade II or active chronic GVHD \\> mild global severity score.\n* Currently taking corticosteroids for therapy at a dose of \\>0.5mg\u002Fkg prednisone equivalent.\n* Patients who have received immunosuppressive treatment (IST) for GVHD within 28 days of infusion.\n* Patients who have received donor lymphocyte infusion (DLI) within 28 days of infusion\n* Any of the following cardiac criteria: Uncontrolled atrial fibrillation\u002Fflutter; Myocardial infarction within the last 12 months; Prolonged QT syndrome or secondary prolonged QT, per investigator discretion; LVSF\\\u003C30% or LVEF\\\u003C50%; or clinically significant pericardial effusion. Cardiac dysfunction NYHA III or IV. \\*Study requires cardiac echocardiography confirmation of absence of these conditions within 12 months of treatment.\n* CNS abnormalities: Presence of CNS-3 disease defined as detectable cerebrospinal blast cells in a sample of CSF with ≥ 5 WBCs per mm3 (unless negative by the Steinherz\u002FBleyer algorithm); Presence of any CNS disorder such as an uncontrolled seizure disorder, cerebrovascular ischemia\u002Fhemorrhage within the past 12 months, dementia, cerebellar disease, or any autoimmune disease with CNS involvement.",{"count":21,"type":22},[25],"Patients eligible for this study have a type of blood cancer called T-cell leukemia or lymphoma (lymph gland cancer).\n\nThe body has different ways of fighting infection and disease. This study combines two different ways of fighting disease with antibodies and T cells. Antibodies are types of proteins that protect the body from bacterial and other diseases. T cells, or T lymphocytes, are special infection-fighting blood cells that can kill other cells including tumor cells. Both antibodies and T cells have been used to treat cancer; they have shown promise, but have not been strong enough to cure most patients.\n\nT cells can kill tumor cells but there normally are not enough of them to kill all the tumor cells. Some researchers have taken T cells from a person's blood, grown more of them in the laboratory and then given them back to the person.\n\nThe antibody used in this study is called anti-CD7. This antibody sticks to T-cell leukemia or lymphoma cells because of a substance on the outside of these cells called CD7. CD7 antibodies have been used to treat people with T-cell leukemia and lymphoma. For this study, anti-CD7 has been changed so that instead of floating free in the blood it is now joined to the T cells. When an antibody is joined to a T cell in this way it is called a chimeric receptor.\n\nIn the laboratory, investigators have also found that T cells work better if they also add proteins that stimulate T cells, such as one called CD28. Adding the CD28 makes the cells grow better and last longer in the body, thus giving the cells a better chance of killing the leukemia or lymphoma cells.\n\nIn this study, investigators attach the CD7 chimeric receptor with CD28 added to it to T cells. Investigators will then test how long the cells last. These CD7 chimeric receptor T cells with CD28 are investigational products not approved by the Food and Drug Administration.",[493,494,495],"T-cell Acute Lymphoblastic Lymphoma","T-non-Hodgkin Lymphoma","T-cell Acute Lymphoblastic Leukemia",[497,498,499,495],"Autologous CAR T cells","T-cell acute lymphoblastic lymphoma","T-non-Hodgkin lymphoma","2026-05-14",{"date":502,"type":44},"2026-05-18",{"date":504,"type":44},"2026-05-12",{"date":506,"type":22},"2043-12",{"name":50,"class":51},{"id":509,"slug":510,"hasResults":12,"nctId":511,"briefTitle":512,"officialTitle":513,"acronym":4,"eligibilityCriteria":514,"healthyVolunteers":88,"sex":17,"minAge":60,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":23,"phases":518,"briefSummary":519,"conditions":520,"keywords":522,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":525,"startDateStruct":526,"completionDateStruct":528,"leadSponsor":530,"locationsCount":52},"100204653","phase-1-experimental-infection-of-hookworm-nave-adults-with-dermally-applied-infectious-necator-americanus-hookworm-larvae-100204653","NCT01940757","Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae","An Experimental Infection Study of Dermally-applied Infectious Necator Americanus Hookworm Larvae in Hookworm-naïve Adults","Inclusion Criteria:\n\n* Males or females between 18 and 45 years, inclusive.\n* Good general health as determined by means of the screening procedure.\n* Available for the duration of the trial (6 months).\n* Willingness to participate in the study as evidenced by signing the informed consent document.\n\nExclusion Criteria:\n\n* Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).\n* Participant unwilling to use reliable contraception methods while participating in the study (if female and not surgically sterile, abstinent or at least 2 years post-menopausal).\n* Currently lactating and breast-feeding (if female).\n* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and\u002For laboratory studies.\n* Known or suspected immunodeficiency.\n* Laboratory evidence of liver disease (alanine aminotransferase \\[ALT\\] greater than 1.25-times the upper reference limit).\n* Laboratory evidence of renal disease (serum creatinine greater than 1.25-times the upper reference limit, or more than trace protein or blood on urine dipstick testing).\n* Laboratory evidence of hematologic disease (hemoglobin \\\u003C11.5 g\u002Fdl \\[females\\] or \\\u003C12.5 g\u002Fdl \\[males\\]; absolute leukocyte count \\\u003C3.6 or \\>10.7 x 103\u002Fmm3; absolute neutrophil count \\[ANC\\] \\\u003C1.7 x 103\u002Fmm3; absolute lymphocyte count \\\u003C0.7 x 103\u002Fmm3; or platelet count \\\u003C140 x 103\u002Fmm3).\n* History of iron deficiency anemia.\n* History of hypoalbuminemia.\n* Laboratory evidence of a coagulopathy (PTT or PT INR greater than 1.1-times the upper reference limit).\n* Serum glucose (random) greater than 1.2-times the upper reference limit.\n* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.\n* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.\n* History of a severe allergic reaction or anaphylaxis.\n* Severe asthma as defined by the need for daily use of inhalers or emergency clinic visit or hospitalization within 6 months of the volunteer's expected Day 0 of the study.\n* Positive ELISA for hepatitis B surface antigen (HBsAg).\n* Positive confirmatory test for HIV infection.\n* Positive confirmatory test for hepatitis C virus (HCV) infection.\n* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of the volunteer's expected Day 0 of this study or planned use during the study.\n* Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to the volunteer's expected Day 0 of the study.\n* Receipt of blood products within the past 6 months.\n* Known allergy to amphotericin B or gentamicin.\n* History of previous infection with hookworm or residence for more than 6 months in a hookworm-endemic area.","45 Years",{"count":517,"type":22},35,[25],"An experimental hookworm infection model is being developed to provide early proof-of-concept that a hookworm vaccine targeting the blood-feeding pathway of adult hookworms is feasible and efficacious. The proposed model consists of vaccinating healthy, hookworm-naïve adults with a candidate hookworm vaccine, followed by challenging them with the investigational product, Necator americanus Larval Inoculum to assess the effect of vaccination on infection. The first proposed study will be a feasibility study that will consist of administering different doses of the Necator americanus Larval Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of infectious larvae) that is safe, well-tolerated and results in consistent infection.",[521],"Hookworm Infection",[523,521,524],"Necator americanus","Experimental challenge infection",{"date":502,"type":44},{"date":527,"type":44},"2015-01",{"date":529,"type":22},"2027-12",{"name":50,"class":51},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":538,"targetDuration":18,"studyType":114,"phases":4,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":52},"100496725","genetic-disorders-of-obesity-program-database-100496725","NCT05747976","Genetic Disorders of Obesity Program Database","GDOP","Inclusion Criteria:\n\n* For individuals 2 years and older, BMI \\> 97 percentile\n* For individuals \\\u003C 2 years old, weight-to-length ratio \\> 95th percentile\n\nExclusion Criteria:\n\n* No other exclusion criteria",{"count":539,"type":22},500,"This study collects data on children with severe, early-onset obesity.",[542,543],"Obesity, Childhood","Genetic Disease","2026-05-07",{"date":504,"type":44},{"date":547,"type":44},"2020-08-30",{"date":549,"type":22},"2030-12-31",{"name":50,"class":51},{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":17,"minAge":111,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":23,"phases":560,"briefSummary":561,"conditions":562,"keywords":566,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":573,"startDateStruct":574,"completionDateStruct":575,"leadSponsor":577,"locationsCount":52},"100580283","novel-brain-stimulation-treatment-for-neuropsychiatric-symptoms-in-alzheimers-disease-100580283","NCT06835283","Novel Brain Stimulation Treatment for Neuropsychiatric Symptoms in Alzheimer's Disease","Sequential Accelerated ITBS \u002F Remote tDCS for Treatment of Neuropsychiatric Symptoms in Alzheimer's Disease: A Pilot Study","Inclusion criteria\n\n1. veteran between the ages of 60 to 85\n2. clinical diagnosis of mild to moderate Alzheimer's disease or related dementia\n3. clinically significant neuropsychiatric symptoms (NPS) evidenced by a score ≥ 2 in at least one domain of the Neuropsychiatric Inventory Questionnaire\n4. mild to moderate cognitive impairment demonstrated by a Mini-Mental State Examination (MMSE) score of 15-23\n5. have a caregiver who is able and willing to escort the patient to\u002Ffrom clinic visits, answer questionnaires, and assist in the implementation of treatment sessions at home\n6. if taking psychotropic medications, demonstrate stability for at least 4 weeks of treatment\n\nExclusion Criteria:\n\n1. any contraindication for MRI\n2. any contraindication for iTBS\u002FtDCS including but not limited to seizure disorder, severe cardiovascular disease, history of brain surgery, or stroke involving the cerebral cortex near area of stimulation\n3. current alcohol or substance use disorder determined by QuickSCID (nicotine allowed; mild cannabis and alcohol use is allowed)\n4. neuropsychiatric symptoms (NPS) that are severe enough to preclude the intervention from being delivered safely and effectively, particularly agitation or aggression.\n\n6\\) any unstable coexisting medical condition that in the opinion of the principal investigator(s) interferes with the treatment protocol or increase the likelihood of adverse events.","85 Years",{"count":113,"type":22},[92],"The goal of this pilot study is to test a combination of two non-invasive brain stimulation methods, called iTBS (intermittent theta burst stimulation) and tDCS (transcranial direct current stimulation), in people with Alzheimer's Disease (AD) and related dementias (ADRD). This study will also explore whether the combined treatment shows promise for reducing neuropsychiatric symptoms like mood swings, apathy, and agitation, and will evaluate the impact of the treatment on caregivers.\n\nThe main questions the study aims to answer are:\n\n1. Is the combined brain stimulation treatment practical and well-tolerated?\n2. Do preliminary results suggest that this treatment could help manage neuropsychiatric symptoms and support a larger study?\n\nParticipants will:\n\n* Attend nine in-person visits over three months.\n* Complete one week of in-clinic brain stimulation sessions (iTBS) followed by four weeks of daily at-home brain stimulation sessions (tDCS).\n* Take part in brain scans, questionnaires, and brain activity tests before and after the treatment.\n\nThis pilot study is a first step to assess whether this combined treatment approach is practical and whether it has potential to improve symptoms, laying the groundwork for larger studies in the future.",[563,564,565],"Alzheimer&Amp;#39;s Disease-related Dementia","Alzheimer Disease","rTMS Stimulation",[567,568,569,570,571],"Alzheimer's Disease","tDCS","iTBS","brain stimulation","mood swings","2026-05-05",{"date":544,"type":44},{"date":261,"type":22},{"date":576,"type":22},"2027-08",{"name":50,"class":51},{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":586,"maxAge":466,"enrollmentInfo":587,"targetDuration":4,"studyType":23,"phases":589,"briefSummary":590,"conditions":591,"keywords":593,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":598,"startDateStruct":599,"completionDateStruct":600,"leadSponsor":601,"locationsCount":265},"100571706","transcutaneous-vagus-nerve-stimulation-for-attention-and-memory-100571706","NCT06723743","Transcutaneous Vagus Nerve Stimulation for Attention and Memory","Transcutaneous Auricular Vagus Nerve Stimulation Effects on Attention and Working Memory: A Pilot Study","taVNS","Inclusion Criteria:\n\n* Ages 25-64\n* Right-handedness\n* Veterans with a history of deployment to Operation Iraqi Freedom (OIF), Operation Enduring Freedom (OEF), Operation New Dawn (OND) or other post 9\u002F11 war on terrorism\n* History of PTSD and\u002For depression\n* Military related mild traumatic brain injury\n* If taking psychotropic medication, demonstrate stability for 3 months\n* If taking stimulants, washout period of 12 hours\n\nExclusion Criteria:\n\n* History of neurological, cardiovascular, or pulmonary disease\n* Cardiac arrhythmia (all types)\n* Active suicidal ideation\n* Visible wounds on skin of the left ear\n* Medical implants such as cardiac defibrillators, pacemakers, or deep brain stimulators\n* Pregnancy\n* Completed taVNS in the past 4 weeks\n* Current substance use disorder (exception: mild cannabis use disorder allowed)\n* Current moderate or severe alcohol use disorder\n* Major cognitive disorder","25 Years",{"count":588,"type":22},30,[92],"This clinical trial aims to evaluate whether transcutaneous auricular vagus nerve stimulation (taVNS), a non-invasive brain stimulation method, can improve attention and memory in veterans with traumatic brain injury (TBI) and depression and\u002For posttraumatic stress disorder (PTSD). The study seeks to answer two main questions:\n\n1. Can active taVNS improve attention and memory compared to sham (placebo) stimulation?\n2. Does taVNS affect heart rate variability (HRV)?\n\ntaVNS delivers a gentle electrical current to the vagus nerve through electrodes placed on the ear, targeting brain areas involved in attention and memory without requiring surgery.\n\nThis study uses a crossover design, meaning all participants will experience two sessions: one with active taVNS and one with sham stimulation. The sham session feels similar but does not deliver actual stimulation, allowing researchers to compare the two and understand taVNS's effects on the brain.\n\nIn a single visit, participants will:\n\n* Complete eligibility screening (questionnaires and vital signs).\n* Undergo two sessions (one active and one sham), randomly assigned.\n* Perform attention tasks before and after each session.\n* Have their heart rate monitored during the sessions.\n\nThe findings will help determine whether taVNS could be an effective treatment for improving attention and memory in veterans with TBI.",[592],"Traumatic Brain Injury (TBI) Patients",[594,595,570,596,597],"vagus nerve stimulation","attention","PTSD","depression",{"date":544,"type":44},{"date":46,"type":22},{"date":576,"type":22},{"name":50,"class":51},{"id":603,"slug":604,"hasResults":12,"nctId":605,"briefTitle":606,"officialTitle":607,"acronym":608,"eligibilityCriteria":609,"healthyVolunteers":12,"sex":17,"minAge":60,"maxAge":466,"enrollmentInfo":610,"targetDuration":4,"studyType":23,"phases":611,"briefSummary":612,"conditions":613,"keywords":616,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":572,"lastUpdatePostDateStruct":619,"startDateStruct":621,"completionDateStruct":623,"leadSponsor":625,"locationsCount":265},"100466556","phase-2-growth-hormone-replacement-in-veterans-with-gwi-and-aghd-gwit-100466556","NCT05355272","Growth Hormone Replacement in Veterans With GWI and AGHD (GWIT)","Growth Hormone Replacement Therapy in Veterans With Gulf War Illness and Adult Growth Hormone Deficiency","GWIT","Inclusion Criteria:\n\n1. veteran of the Gulf War conflict with a history of deployment to Operation Desert Storm or Desert Shield between 1990-91\n2. age less than or equal to 64 years old\n3. have a diagnosis of Gulf War Illness assessed by study investigators\n4. have adult growth hormone deficiency diagnosed by glucagon stimulation test (cut point 3.0 mcg\u002FL if BMI is less than or equal to 25 or 1.0 mcg\u002FL if BMI is greater than 25)\n5. 4-week stability on any psychotropic medications\n6. 3-month stability on all hormone treatments\n7. able and willing to provide informed consent to participant in the study and complete study protocol\n\nExclusion Criteria:\n\n1. history of a psychiatric disorder with substantial impact on functional status or quality of life (e.g., schizophrenia, schizoaffective disorder, bipolar, or other psychotic disorder)\n2. history of neurologic disorder other than traumatic brain injury with substantial impact on the quality of life\n3. other known cause for growth hormone deficiency (GHD) including history of childhood onset GHD, hypothalamic\u002Fpituitary disease, history of brain radiation, or genetic mutations known to lead to GHD\n4. active suicidal ideation as determined by a score of 2 points or higher on the Columbia Suicide Severity Rating Scale\n5. suicidal behavior in the past 6 months\n6. contraindication to recombinant human growth hormone (rhGH) such as hypersensitivity to rhGH or any of the components of the supplied product\n7. acute medical illness, active infection, cancer, or decompensated chronic medical illness (e.g., decompensated diabetes mellitus, congestive heart failure, chronic obstructive pulmonary disease)\n8. evidence of substance use disorder in the past 6 months other than mild alcohol or cannabis use disorder diagnosed by clinician at time of screening.\n9. urine toxicology evidence of illicit drug use (excluding cannabis) within the past 90 days prior to screening\n10. BMI \\> 35 or body weight \\> 350 lbs\n11. abnormal pituitary anatomy documented by an MRI using a Sella protocol\n12. women who are pregnant or of child-bearing potential who are unable\u002Funwilling to use one of the following barrier contraceptives: condoms, diaphragm, cervical cap, or intrauterine device\n13. current use of the following: growth hormone, estrogen or estrogen-like dietary supplements, hormonal contraceptives, progestin, insulin growth factor 1 (IGF-1), or chronic glucocorticoid use in supraphysiologic doses\n\n15\\) currently enrolled in any other interventional drug trials unless prior approval is provided by the study chairs and the study sponsor",{"count":113,"type":22},[64],"The goal of the GWIT Study is to assess whether growth hormone replacement therapy is a safe and effective treatment for veterans with Gulf War Illness (GWI) and adult growth hormone deficiency (AGHD). The main questions the study aims to answer are:\n\n1. Is growth hormone effective at reducing fat in the trunk of the body and symptoms of GWI among veterans with GWI and growth hormone deficiency?\n2. Do the results of the study suggest there is merit in pursuing a larger trial to examine the efficacy of growth hormone as a treatment for growth hormone deficiency among veterans with Gulf War Illness?\n\nTo determine eligibility for the study, veterans will be asked to complete several assessments including questionnaires, blood tests, and a scan of the brain. Participants who qualify for the study will receive recombinant human growth hormone for 6-months. A body composition scan will be performed at Day1, Day 90, and Day 180 of the intervention. Questionnaires and cognitive tests will also be collected before and after the trial.",[614,615],"Gulf War Syndrome","Adult Growth Hormone Deficiency",[617,618],"recombinant human growth hormone","growth hormone replacement therapy",{"date":620,"type":44},"2026-05-08",{"date":622,"type":44},"2024-03-11",{"date":624,"type":22},"2027-07-01",{"name":50,"class":51},{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":630,"acronym":631,"eligibilityCriteria":632,"healthyVolunteers":88,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":633,"targetDuration":4,"studyType":114,"phases":4,"briefSummary":635,"conditions":636,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":640,"lastUpdatePostDateStruct":641,"startDateStruct":643,"completionDateStruct":645,"leadSponsor":647,"locationsCount":52},"100538647","microphthalmia-anophthalmia-and-coloboma-genetic-epidemiology-in-children-100538647","NCT06293560","Microphthalmia, Anophthalmia, and Coloboma Genetic Epidemiology in Children","MAGIC","Inclusion Criteria:\n\n1. All MAC cases\n2. Parents of the above children.\n3. Siblings of the above children.\n4. English or Spanish speaking.\n\nExclusion Criteria:\n\nAll subjects who do not meet the inclusion criteria listed above.",{"count":634,"type":22},3000,"The investigators are inviting families to take part in a research study that will help us better understand the physical characteristics associated with children who have Microphthalmia, Anophthalmia, and Coloboma (MAC) and how changes in their DNA sequence, called genetic mutations, play a role in the risk of developing MAC",[637,638,639],"Microphthalmia","Coloboma","Anophthalmia","2026-05-01",{"date":642,"type":44},"2026-05-06",{"date":644,"type":44},"2022-09-25",{"date":646,"type":22},"2027-09",{"name":50,"class":51},""]